RNA Avidity Biosciences Inc
Price (delayed)
$31.12
Market cap
$3.71B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.89
Enterprise value
$3.35B
Avidity Biosciences, Inc. is driven to change lives with a new class of therapies called Antibody Oligonucleotide Conjugates (AOCs) that are designed to overcome current limitations of oligonucleotide therapies in
Highlights
The equity has soared by 191% YoY and by 23% QoQ
RNA's quick ratio has soared by 56% YoY and by 13% from the previous quarter
RNA's net income is down by 39% YoY and by 11% QoQ
The gross profit fell by 4.5% QoQ
Key stats
What are the main financial stats of RNA
Market
Valuations
Earnings
Shares outstanding
119.31M
Market cap
$3.71B
Enterprise value
$3.35B
Price to earnings (P/E)
N/A
Price to book (P/B)
2.27
Price to sales (P/S)
379.5
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
330.88
Revenue
$10.12M
Gross profit
$10.12M
Operating income
-$324.69M
Net income
-$280.49M
EBIT
-$280.49M
EBITDA
-$274.54M
Free cash flow
-$188.51M
Per share
Balance sheet
Liquidity
EPS
-$2.89
EPS diluted
-$2.89
Free cash flow per share
-$1.53
Book value per share
$13.69
Revenue per share
$0.08
TBVPS
$13.3
Total assets
$1.64B
Total liabilities
$137.39M
Debt
$7.6M
Equity
$1.5B
Working capital
$1.53B
Debt to equity
0.01
Current ratio
17.76
Quick ratio
17.42
Net debt/EBITDA
1.33
Margins
Efficiency
Dividend
EBITDA margin
-2,713.6%
Gross margin
100%
Net margin
-2,772.5%
Operating margin
-3,209.4%
Return on assets
-24.6%
Return on equity
-27.7%
Return on invested capital
-42.1%
Return on capital employed
-18.1%
Return on sales
-2,772.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
RNA stock price
How has the Avidity Biosciences stock price performed over time
Intraday
-4.33%
1 week
-3.68%
1 month
0.91%
1 year
116.26%
YTD
7.02%
QTD
7.02%
Financial performance
How have Avidity Biosciences's revenue and profit performed over time
Revenue
$10.12M
Gross profit
$10.12M
Operating income
-$324.69M
Net income
-$280.49M
Gross margin
100%
Net margin
-2,772.5%
The operating income has contracted by 46% YoY and by 14% from the previous quarter
RNA's operating margin is down by 46% year-on-year and by 19% since the previous quarter
RNA's net income is down by 39% YoY and by 11% QoQ
Avidity Biosciences's net margin has decreased by 39% YoY and by 16% from the previous quarter
Growth
What is Avidity Biosciences's growth rate over time
Valuation
What is Avidity Biosciences stock price valuation
P/E
N/A
P/B
2.27
P/S
379.5
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
330.88
RNA's EPS is up by 3.7% YoY and by 2% from the previous quarter
The equity has soared by 191% YoY and by 23% QoQ
The P/B is 13% below the last 4 quarters average of 2.6 and 9% below the 5-year quarterly average of 2.5
RNA's P/S is 159% above its 5-year quarterly average of 146.3 and 22% above its last 4 quarters average of 311.5
RNA's revenue is down by 4.5% since the previous quarter
Efficiency
How efficient is Avidity Biosciences business performance
RNA's ROS is down by 39% YoY and by 16% from the previous quarter
RNA's ROA is up by 26% YoY and by 15% from the previous quarter
The ROE has grown by 24% YoY and by 16% from the previous quarter
RNA's return on invested capital is up by 20% since the previous quarter and by 18% year-on-year
Dividends
What is RNA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for RNA.
Financial health
How did Avidity Biosciences financials performed over time
RNA's total assets has soared by 186% YoY and by 22% QoQ
RNA's total liabilities has surged by 147% year-on-year and by 9% since the previous quarter
Avidity Biosciences's debt is 99% less than its equity
The equity has soared by 191% YoY and by 23% QoQ
Avidity Biosciences's debt to equity has plunged by 50% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.